Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

SIMPLE SUMMARY: This analysis assesses the efficacy of brigatinib, a next-generation ALK inhibitor in ALK(+) advanced non-small cell lung cancer (aNSCLC) included in the brigatinib French Early-Access Program (1 August 2016–21 January 2019), with a focus on post-brigatinib lorlatinib efficacy. With...

Descripción completa

Detalles Bibliográficos
Autores principales: Descourt, Renaud, Pérol, Maurice, Rousseau-Bussac, Gaëlle, Planchard, David, Mennecier, Bertrand, Wislez, Marie, Cadranel, Jacques, Cortot, Alexis Benjamin, Guisier, Florian, Galland, Loïck, Do, Pascal, Schott, Roland, Dansin, Éric, Arrondeau, Jennifer, Auliac, Jean-Bernard, Geier, Margaux, Chouaïd, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997056/
https://www.ncbi.nlm.nih.gov/pubmed/35406523
http://dx.doi.org/10.3390/cancers14071751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997056/
https://www.ncbi.nlm.nih.gov/pubmed/35406523
http://dx.doi.org/10.3390/cancers14071751

Ejemplares similares